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Data on outcomes of allogeneic transplantation in children with Down syndrome and acute myelogenous
leukemia (DS-AML) are scarce and conﬂicting. Early reports stress treatment-related mortality as the main
barrier; a recent case series points to posttransplantation relapse. We reviewed outcome data for 28 patients
with DS-AML reported to the Center for International Blood and Marrow Transplant Research between 2000
and 2009 and performed a ﬁrst matched-pair analysis of 21 patients with DS-AML and 80 non-DS AML
controls. The median age at transplantation for DS-AML was 3 years, and almost half of the cohort was in
second remission. The 3-year probability of overall survival was only 19%. In multivariate analysis, adjusting
for interval from diagnosis to transplantation, risks of relapse (hazard ratio [HR], 2.84; P < .001; 62% versus
37%) and transplant-related mortality (HR, 2.52; P ¼ .04; 24% versus 15%) were signiﬁcantly higher for DS-
AML compared to non-DS AML. Overall mortality risk (HR, 2.86; P < .001; 21% versus 52%) was signiﬁ-
cantly higher for DS-AML. Both transplant-related mortality and relapse contribute to higher mortality. Excess
mortality in DS-AML patients can only effectively be addressed through an international multicenter effort to
pilot strategies aimed at lowering both transplant-related mortality and relapse risks.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION acute leukemia compared to the general pediatric population
Allogeneic hematopoietic cell transplantation (HCT) is an
integral part of treatment for high-risk acute myelogenous
leukemia (AML) in children and adolescents. Disease-free
survival (DFS) for pediatric AML after HCT ranges between
40% and 60%, and varies depending on donor and graft source
[1-3]. For patients with Down syndrome (DS) and acute
leukemia, the role of HCT remains unclear. Children with DS
(OMIM, #190685) have a 10- to 20-fold increased risk fordgments on page 897.
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13.02.017[4]. AML in DS (DS-AML) is characterized by young age of
onset, somatic mutations of the hematopoietic transcription
factor GATA1, and excellent outcomes with chemotherapy
(DFS of 80%) [5-7] because of the increased drug sensitivity of
DS-AML blasts, especially in the younger patients, most of
whomhaveM7disease [8]. Consequently, HCT is not typically
considered for DS-AML in ﬁrst remission. For patients beyond
ﬁrst remission, allogeneic transplantation may be offered;
however, data are scarce and the pattern of treatment failure
is unclear. An earlier report of 27 patients with DS and AML or
acute lymphoblastic leukemia suggested treatment-related
mortality (TRM) was the predominant cause of treatment
failure [9], although a later report of 11 patients suggested
relapse as the primary cause of treatment failure [10]. To ourTransplantation.
Table 1
Patient, Disease and Transplant Characteristics
Number of patients 28
Number of transplant centers 24
Age, median (range), yr 3 (2-24)
Age, 5 yr 25
Age, 6 to 18 yr 2
Age, >18 yr 1
Lansky performance score
<90 1
90 to 100 25
Not reported 2
Disease status
First complete remission 5
Second complete remission* 12
Relapse 9















Time from diagnosis to transplantation
12 mo 18
13 to 36 mo 10
Conditioning regimen
Total body irradiation þ cyclophosphamide 7
Total body irradiation þ other agents 2
Busulfan þ cyclophosphamide 13
Busulfan þ ﬂudarabine 2
Busulfan þ melphalan 4








HLA-matched sibling (BM 1, PBSC 3, CB 0) 4
HLA-matched unrelated donor (BM 5, PBSC 2, CB 2) 9
HLA-mismatched unrelated donor (BM 2, PBSC 1, CB 12) 15
Graft type
Bone marrow 8
Peripheral blood progenitor cells 6
Umbilical cord blood 14
Transplant period
2000 to 2005 17
2005 to 2009 11
Median follow-up, (range), mo 47 (7-60)
ATG indicates anti-thymocyte globulin; HLA, human leukocyte antigen; BM,
bone marrow; PBSC, peripheral blood stem cells; CB, cord blood.
Data are presented as n unless otherwise indicated.
* Duration 4.8 to 22.0 months.
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transplant outcomes for AML in patients with or without DS.
Therefore, to better deﬁne patterns of posttransplantation
treatment failure we conducted a matched-pair analysis of
patients with DS-AML and non-DS AML.
PATIENTS AND METHODS
Data Source
Data were obtained from the Center for International Blood andMarrow
Transplant Research, which is a working group of more than 400 transplant
centers worldwide that provide detailed patient, disease, and transplant
characteristics and outcomes on consecutive transplantations to the statis-
tical center at the Medical College of Wisconsin or the data-coordinating
center of the National Marrow Donor Program. Participating centers
report data on consecutive transplantations; all patients are followed
longitudinally until death or lost to follow-up. Guardians provided written
informed consent for data submission and research participation. The
Institutional Review Boards of the Medical College of Wisconsin and the
National Marrow Donor Program approved this study.
Inclusion Criteria
Patients with DS-AML who received grafts from human leukocyte
antigen (HLA)-matched siblings, and matched or mismatched unrelated
adult donors or umbilical cord blood were eligible. A similar population of
non-DS AML patients served as controls. All transplantations occurred
between 2000 and 2009. Transplantations before 2000 were excluded
because of substantial changes in front-line chemotherapeutic regimens and
supportive care after transplantation.
Risk Classiﬁcation
Risk classiﬁcation was assigned based on cytogenetic and molecular
markers. Patients were classiﬁed into 3 risk groups: the favorable risk group
included the t(8;21), t(15;17) and inv(16) karyotypes; high risk was deﬁned
by the presence of -7, -5, del (5q), abnormalities of the long arm of chro-
mosome 3 or complex karyotype that was deﬁned as more than 4 abnor-
malities; all other AML karyotypes were classiﬁed as intermediate risk [11].
Blast phenotype was not used for risk stratiﬁcation or matching of cases and
controls (see below). This approach is consistent with the exclusion of blast
phenotype from contemporary prognostication and treatment stratiﬁcation
of AML in children with [5,7,12] and without DS [2,11,13]. FLT3 mutations
were not considered, as this information was not systematically collected in
the early 2000s.
Outcomes
Neutrophil recovery was deﬁned by an absolute neutrophil count (ANC)
500/ml for 3 consecutive measurements; platelet recovery as a platelet
count >20,000/mL for 7 days without transfusion. Grades 2 to 4 acute graft-
versus-host disease (GVHD) and chronic GVHDwere deﬁned using standard
criteria [14,15]. TRM was deﬁned as death occurring in remission. Relapse
was deﬁned as morphological recurrence of leukemia at any site. DFS
(inverse of treatment failure; relapse, or death) was deﬁned as survival in
continuous complete remission. Surviving patients were censored at last
contact.
Statistical Analyses
The probabilities of neutrophil and platelet recovery, acute and chronic
GVHD, TRM, and relapse were calculated using the cumulative incidence
function estimator [16]. For neutrophil and platelet recovery and GVHD,
death without the event was the competing risk. For TRM, relapse was the
competing event, and for relapse, TRM was the competing event. The
probabilities of DFS and overall survival were calculated using the Kaplan-
Meier estimator [16]. The 95% conﬁdence intervals were calculated using
log transformation. For overall survival, death from any cause was consid-
ered an event, and for DFS, relapse or death were considered events.
Patients with DS-AML (cases) were matched to patients with non-DS
AML (controls). Cases and controls were matched on disease status, risk
group, donor and graft source, and donor-recipient HLAmatch. Additionally,
matched pairs with the smallest age difference between the case and
controls were selected. Among the 28 patients with DS-AML, 7 patients
were excluded from the matched analysis: age >18 years (n ¼ 1), reduced-
intensity conditioning regimen (n ¼ 1), absence of cytogenetic data (n ¼ 4),
or control case not available (n ¼ 1). Twenty-one cases were matched to 80
controls from a population of 746 controls: 18 pairs matched 1:4, 2 pairs
matched 1:3, and 1 pair matched 1:2. All patients included in the matched
pair analysis received myeloablative transplant conditioning regimen. Cox
regression models [16] were built to examine the risk of relapse, TRM,
treatment failure, and overall mortality for patients with DS-AML and non-DS AML. As cases and controls were matched on known prognostic factors,
the only additional variable considered was interval from diagnosis to
transplantation (12 months versus >12 months) to adjust for the prog-
nostic impact of early relapse. All P values are 2-sided and value .05 was
considered signiﬁcant. All analyses were performed using SAS version 9.1
(Cary, NC).RESULTS
Patient, disease, and transplant characteristics for all
patients with DS-AML are shown in Table 1. The median age







Neutrophil recovery 24 of 28
At 28 d 75 (58-89)
Platelet recovery 15 of 25
At 100 d 52 (31-69)
Grades 2 to 4 acute graft-versus-host
disease
8 of 28
At 100 d 29 (14-46)
Chronic graft-versus-host disease 6 of 28
At 3 yr 23 (9-40)
Transplant-related mortality 7 of 28
At 100 d 14 (4-29)
At 3 yr 25 (11-42)
Relapse 17 of 28
At 3 yr 61 (42-78)
Disease-free survival 24 of 28
At 3 yr 14 (4-29)
Overall survival 23 of 28
At 3 yr 19 (7-36)
Table 3
Characteristics of DS-AML and Non DS-AML Patients Matched for Age,






Number of patients 80 21
Number of centers 47 19
Age
5 yr 60 (75) 19 (90)
6 to 10 yr 14 (18) 1 (5)
11 to 18 yr 6 (8) 1 (5)
Sex
Male 54 (68) 13 (62)
Female 26 (33) 8 (38)
Lansky performance score
<90 16 (20) 1 (5)
90 60 (75) 18 (86)
Unknown 4 (5) 2 (10)
Time from diagnosis to transplant, mo
12 mo 46 (58) 13 (62)
13 to 36 mo 34 (43) 8 (38)
Disease status prior to transplantation
First remission 16 (20) 4 (19)
Second remission 36 (45) 9 (43)
Relapse 16 (20) 7 (33)
Primary induction failure 12 (15) 1 (5)
Blast phenotype (FAB)
M0 3 (4) 2 (10)
M1 5 (6) 1 (5)
M2 15 (19) 1 (5)
M3 1 (1) 0
M4 5 (6) 1 (5)
M5 25 (31) 0
M6 3 (4) 0
M7 10 (13) 12 (57)
Not speciﬁed 13 (16) 4 (19)
Risk groups
Intermediate risk 67 (84) 17 (81)
High risk 13 (16) 4 (19)
Conditioning regimen
Total body irradiation þ cyclophosphamide 38 (48) 6 (29)
Total body irradiation þ other agents 4 (5) 2 (10)
Busulfan þ cyclophosphamide 25 (31) 10 (48)
Busulfan þ ﬂudarabine 4 (5) 0
Busulfan þ melphalan 9 (11) 3 (14)
Graft-versus-host disease prophylaxis
Cyclosporine-containing 64 (80) 15 (71)
Tacrolimus-containing 11 (14) 5 (24)
Methotrexate 3 (3) 0
Not reported 3 (3) 1 (5)
Donor type













Bone marrow 24 (30) 6 (29)
Peripheral blood progenitor cells 13 (16) 4 (19)
Umbilical cord blood 43 (54) 11 (52)
Median (range) follow-up, mo 37 (3-120) 47 (7-60)
BM indicates bone marrow; PBSC, peripheral blood stem cells; CB, cord
blood.
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Forty-three percent of transplantations occurred in second
remission and 39% in relapse or after primary induction
failure. Most patients were transplanted for early treatment
failure, as 64% of patients were transplanted within a year
from diagnosis. All but one patient received myeloablative
transplant-conditioning regimens. Grafts from mismatched
unrelated donors or umbilical cord blood units each
accounted for 40% of all transplantations and HLA-
mismatching was almost entirely conﬁned to the cord
blood grafts. All patients received cyclosporine or tacrolimus
containing GVHD prophylaxis and approximately 30%
received methotrexate or mycophenolate mofetil with the
calcineurin inhibitor.
The probabilities of hematopoietic recovery, GVHD, TRM,
relapse, DFS, and OS are shown in Table 2. The TRM rate was
high, but the relapse rate was substantially higher for DS-
AML than non-DS AML patients. One patient with DS-AML
age 24 years was included in the unmatched analysis and
should not have signiﬁcantly inﬂuenced the aforementioned
poor outcomes. An additional univariate analysis restricted
to patients age 18 years or younger at transplantation
conﬁrmed that no differences emerged when this young
adult was excluded (data not shown). Only 4 of 28 patients
are alive and disease-free. Of the 23 patients who are dead,
16 (70%) died of recurrent disease. Other causes of death
include organ failure (n ¼ 4), hemorrhage (n ¼ 1), infection
(n ¼ 1) and cause of death not reported (n ¼ 1). One patient
who relapsed is alive at last follow-up.
The characteristics of cases (DS-AML; n¼ 21) and controls
(non-DS AML; n ¼ 80) are shown in Table 3. Figure 1A
through 1D show the probabilities of relapse, TRM, DFS,
and overall survival of cases (DS-AML) and controls (non-DS
AML). Consistent with the results of univariate analysis, in
multivariate analysis, after adjusting for interval from diag-
nosis to transplantation, risks of TRM, relapse, treatment
failure (inverse of DFS), and overall mortality are signiﬁcantly
higher in DS-AML patients compared with non-DS AML
(Table 4).
DISCUSSION
Although chemotherapy approaches are now well
deﬁned for DS-AML [5,7,8,17-20], the role of allogeneic
transplantation has been limited to case reports and smallseries [21] that aremore pertinent to previous treatment eras
[22], and the results are conﬂicting [9,10,22]. Our current
analysis sought to delineate the relative contributions of
TRM and relapse to treatment failure after allogeneic
Figure 1. (A) The 3-year probabilities of TRM: 24% (95% CI, 9% to 44%) and 15% (95% CI, 8% to 24%) for DS-AML and non-DS AML, respectively (P ¼ .04). (B) The 3-year
probabilities of relapse: 62% (95% CI, 41% to 81%) and 37% (95% CI, 27% to 48%), for DS-AML and non-DS AML, respectively (P < .001). (C) The 3-year probabilities of
DFS: 14% (95% CI, 3% to 32%) and 48% (95% CI, 37% to 59%) for DS-AML and non-DS AML, respectively (P < .001). (D) The 3-year probabilities of overall survival: 21%
(95% CI, 6% to 42%) and 52% (95% CI, 41% to 63%), for DS-AML and non-DS AML, respectively (P < .001).
J.K. Hitzler et al. / Biol Blood Marrow Transplant 19 (2013) 893e897896transplantation in a relatively large contemporary cohort of
patients with DS-AML and our ﬁndings conﬁrm that high
rates of TRM and relapse both play a role. Conﬁrmation of
this observation was strengthened by the additional
matched pair analyses of DS-AML and non-DS AML patients
that adjusted for risk factors associated with transplantation
outcomes. High rates of treatment failure led to an overall
survival rate of only 21% after transplantation for DS-AML
compared to 52% for non-DS AML.
It is tempting to attribute high relapse rates in our DS-
AML cohort to the 39% of patients whose leukemia wasTable 4





DS-AML versus non DS-AML* 2.52 (1.06-6.00) .04
Time from diagnosis to transplantation
12 mo versus 13 to 36 mo* 2.17 (0.75-6.25) .15
Relapse
DS-AML versus non DS-AML* 2.84 (1.75-4.59) <.001
Time from diagnosis to transplantation
12 mo versus 13 to 36 mo* 1.43 (0.76-2.63) .27
Treatment failure
DS-AML versus non DS-AML* 2.75 (1.75-4.31) <.001
Time from diagnosis to transplantation
12 mo versus 13 to 36 mo* 1.59 (0.92-2.78) .10
Overall mortality
DS-AML versus non DS-AML* 2.86 (1.77-4.64) <.001
Time from diagnosis to transplantation
12 mo versus 13 to 36 mo* 1.89 (1.05-3.45) .03
* Reference group.active at transplantation. However, results from our matched
pair comparison do not support this notion. Therefore, the
reported overall favorable prognosis of DS-AML at time of
original diagnosis appears to reﬂect outcomes in 2 different
risk settings: one where over 80% of patients achieve long-
term remission with lower intensity chemotherapy alone
[5-7], and a smaller percentage, who respond poorly to up
front therapy [23] as manifested by early relapse and
inability to achieve complete remission after a relapse.
The current analysis used data reported to a transplant
registry. A signiﬁcant limitation is the heterogeneity of the
patients with respect to their disease status at trans-
plantation and transplant-conditioning regimen. However,
we were able to perform a carefully controlled analysis
adjusting for the known risk factors that inﬂuence trans-
plantation outcomes. The observed poor outcome may be
attributed to differences in the biology of DS-AML and/or the
intensity of front-line chemotherapy regimens used in these
patients compared to non-DS AML patients. Another plau-
sible explanation could be the presence of minimal residual
disease (MRD) at transplantation; data on MRD were not
collected during the study period and is a limitation.
Our data suggest a reduction in TRM remains desirable,
but the data also highlight the importance of leukemia
recurrence as a major cause of treatment failure. Therefore,
the decision to offer transplant for DS-AML must consider
the excess risk of leukemia recurrence after transplantation
even for those who attain remission after an initial relapse
in addition to TRM risks. One strategy to improve survival
could focus on carefully selecting transplant candidates
such as those in morphological remission and who are
J.K. Hitzler et al. / Biol Blood Marrow Transplant 19 (2013) 893e897 897MRD negative. Other strategies include planned post-
transplantation therapy to ensure better leukemia control
posttransplantation. Lowering TRM risks remains a challenge
in these patients; full intensity regimens, which offer
leukemia control, are offset by life-threatening infections
and/or organ toxicity.ACKNOWLEDGMENTS
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